Animas' pumps help diabetic patients to stay animated. The company's computerized insulin pumps are pager-sized devices that diabetes patients "wear" and which continuously deliver rapid-acting insulin into the body. The infusion pumps, which are connected to a tube with a needle at the end that's inserted under the skin, replace the use of periodic insulin injections. Animas also sells diabetes management software, monitors, and various pump accessories. It markets its products worldwide through a combination of direct sales representatives and distributors. The company is a subsidiary of Johnson & Johnson, reporting to J&J's LifeScan division.
The company operates in Australia, Canada, Ireland, Israel, Mexico, New Zealand, Puerto Rico, the UK, Continental Europe, and the US.
Animas is a positive growth contributor in J&J's diabetes care operations, and together with glucose monitor maker LifeScan it contributes about 5% of the parent's annual revenues. Sales of Animas' insulin pumps have also expanded through additional product development efforts, as well as entries into new international markets.
While the company is focused on marketing its OneTouch Ping offering, Animas has several other insulin pumps on the market, including the Animas 2020. Earlier models include the Animas 1250 and 1200 versions. The firm is also the exclusive distributor of the inset and inset 30 line of insulin infusion sets made by Unomedical (a ConvaTec unit); the sets connect to the Animas pumps as well as pumps made by other manufacturers. It also distributes the Seven CGM (continuous glucose monitor) made by DexCom.
Animas is also working with DexCom to integrate the CGM technology into the Animas insulin pumps.In 2011 the company received the European CE Mark approval for Animas Vibe, a continuous glucose monitoring enabled insulin pump system with Dexcom CGM G4 technology. It plans to launch this product in the UK, Germany, France, Italy, and Sweden.
The CGM system, which continuously reads glucose levels through a small sensor inserted just below the skin, transmits readings to the pump, which automatically administers insulin as needed.
The company is a subsidiary of Johnson & Johnson.
Following the acquisition of Animas in 2006, Johnson & Johnson combined the Animas and OneTouch technologies to create the Ping system, a glucose management system that includes a meter/remote that monitors and controls the system's insulin pump. – less
7 salaries reported
$106,493 per year
3 salaries reported
$50,658 per year
3 salaries reported
$58,927 per year